Quality of life in spondyloarthritis patients receiving biological therapy
Spondyloarthritides (SpAs) is a group of chronic inflammatory diseases of the spine, joints, and entheses characterized by common clinical, radiological, and genetic features. According to international guidelines, one of the main goals of SpA treatment is to ensure the longest possible preservation...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA-PRESS LLC
2019-10-01
|
| Series: | Современная ревматология |
| Subjects: | |
| Online Access: | https://mrj.ima-press.net/mrj/article/view/955 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849691583801196544 |
|---|---|
| author | A. I. Akulova K. D. Dorogoikina I. Z. Gaydukova A. P. Rebrov |
| author_facet | A. I. Akulova K. D. Dorogoikina I. Z. Gaydukova A. P. Rebrov |
| author_sort | A. I. Akulova |
| collection | DOAJ |
| description | Spondyloarthritides (SpAs) is a group of chronic inflammatory diseases of the spine, joints, and entheses characterized by common clinical, radiological, and genetic features. According to international guidelines, one of the main goals of SpA treatment is to ensure the longest possible preservation of the patient's quality of life (QOL). The use of biological agents (BAs) allows rapid clinical improvement and positively affects QOL in patients.Objective: to evaluate the efficacy of BAs on QOL in patients with SpA in real clinical practice.Patients and methods. A total of 280 patients with SpA were examined. The inclusion criteria were ≥18 years of age; compliance of the clinical picture of the disease with the ASAS criteria for axial SpA (2009) or peripheral SpA (2011); and signing the informed consent form. Disease activity was assessed using the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and the Ankylosing Spondylitis Disease Activity Score (ASDAS); the functional status of the patients was estimated by the Bath Ankylosing Spondylitis Functional Index (BASFI), and their spinal mobility was evaluated by the Bath Ankylosing Spondylitis Metrology Index (BASMI); ASAS HI was used to comprehensively evaluate the impact of SpA on the patient's health. The European QL EQ-5D-5L and the SF-36 questionnaire were applied to determine quality of life in the patients.Results and discussion. The patients' mean age was 40.19±11.9 years; there was a male preponderance (64%); the HLA-B7-pisitive patients were 78%. The median scores were 5.40 [3.12; 6.80] for BASDAI, 3.37 [2.58; 4.15] for ASDAS, 5.30 [2.60; 7.50] for BASFI, 4.00 [2.60; 6.15] for BASMI, and 9.00 [7.00; 12.00] for ASAS HI. Forty-four patients received a variety of BAs. Patients receiving and not receiving BAs were matched for age and gender; however, the patients on biological therapy (BT) had longer disease duration and lower disease activity according to the ASDAS. There were no statistically significantly difference between the two groups in disease activity according to the BASDAI and in functional disorders according to the BASFI; but there was a tendency towards lower values in the patients on BT. Comparison of QOL in the patients of the two groups revealed statistically significant differences in SF-36 pain scale scores (p=0.02) and EQ-5D-5L indicators (p<0.01).Conclusion. BT makes it possible to successfully achieve one of the main goals of treating patients with SpA, namely to preserve QOL. The patients receiving BAs had longer disease duration, while they were comparable to those not receiving this treatment in terms of the degree of functional disorders. |
| format | Article |
| id | doaj-art-fd6a6d9b0d9347ee9aa1bfaf3f1a29cd |
| institution | DOAJ |
| issn | 1996-7012 2310-158X |
| language | Russian |
| publishDate | 2019-10-01 |
| publisher | IMA-PRESS LLC |
| record_format | Article |
| series | Современная ревматология |
| spelling | doaj-art-fd6a6d9b0d9347ee9aa1bfaf3f1a29cd2025-08-20T03:20:59ZrusIMA-PRESS LLCСовременная ревматология1996-70122310-158X2019-10-01134364010.14412/1996-7012-2019-4-36-402207Quality of life in spondyloarthritis patients receiving biological therapyA. I. Akulova0K. D. Dorogoikina1I. Z. Gaydukova2A. P. Rebrov3V.I. Razumovsky Saratov State Medical University, Ministry of Health of RussiaV.I. Razumovsky Saratov State Medical University, Ministry of Health of RussiaI.I. Mechnikov North-Western State Medical University, Ministry of Health of RussiaV.I. Razumovsky Saratov State Medical University, Ministry of Health of RussiaSpondyloarthritides (SpAs) is a group of chronic inflammatory diseases of the spine, joints, and entheses characterized by common clinical, radiological, and genetic features. According to international guidelines, one of the main goals of SpA treatment is to ensure the longest possible preservation of the patient's quality of life (QOL). The use of biological agents (BAs) allows rapid clinical improvement and positively affects QOL in patients.Objective: to evaluate the efficacy of BAs on QOL in patients with SpA in real clinical practice.Patients and methods. A total of 280 patients with SpA were examined. The inclusion criteria were ≥18 years of age; compliance of the clinical picture of the disease with the ASAS criteria for axial SpA (2009) or peripheral SpA (2011); and signing the informed consent form. Disease activity was assessed using the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and the Ankylosing Spondylitis Disease Activity Score (ASDAS); the functional status of the patients was estimated by the Bath Ankylosing Spondylitis Functional Index (BASFI), and their spinal mobility was evaluated by the Bath Ankylosing Spondylitis Metrology Index (BASMI); ASAS HI was used to comprehensively evaluate the impact of SpA on the patient's health. The European QL EQ-5D-5L and the SF-36 questionnaire were applied to determine quality of life in the patients.Results and discussion. The patients' mean age was 40.19±11.9 years; there was a male preponderance (64%); the HLA-B7-pisitive patients were 78%. The median scores were 5.40 [3.12; 6.80] for BASDAI, 3.37 [2.58; 4.15] for ASDAS, 5.30 [2.60; 7.50] for BASFI, 4.00 [2.60; 6.15] for BASMI, and 9.00 [7.00; 12.00] for ASAS HI. Forty-four patients received a variety of BAs. Patients receiving and not receiving BAs were matched for age and gender; however, the patients on biological therapy (BT) had longer disease duration and lower disease activity according to the ASDAS. There were no statistically significantly difference between the two groups in disease activity according to the BASDAI and in functional disorders according to the BASFI; but there was a tendency towards lower values in the patients on BT. Comparison of QOL in the patients of the two groups revealed statistically significant differences in SF-36 pain scale scores (p=0.02) and EQ-5D-5L indicators (p<0.01).Conclusion. BT makes it possible to successfully achieve one of the main goals of treating patients with SpA, namely to preserve QOL. The patients receiving BAs had longer disease duration, while they were comparable to those not receiving this treatment in terms of the degree of functional disorders.https://mrj.ima-press.net/mrj/article/view/955spondyloarthritisankylosing spondylitisquality of lifebiological therapy |
| spellingShingle | A. I. Akulova K. D. Dorogoikina I. Z. Gaydukova A. P. Rebrov Quality of life in spondyloarthritis patients receiving biological therapy Современная ревматология spondyloarthritis ankylosing spondylitis quality of life biological therapy |
| title | Quality of life in spondyloarthritis patients receiving biological therapy |
| title_full | Quality of life in spondyloarthritis patients receiving biological therapy |
| title_fullStr | Quality of life in spondyloarthritis patients receiving biological therapy |
| title_full_unstemmed | Quality of life in spondyloarthritis patients receiving biological therapy |
| title_short | Quality of life in spondyloarthritis patients receiving biological therapy |
| title_sort | quality of life in spondyloarthritis patients receiving biological therapy |
| topic | spondyloarthritis ankylosing spondylitis quality of life biological therapy |
| url | https://mrj.ima-press.net/mrj/article/view/955 |
| work_keys_str_mv | AT aiakulova qualityoflifeinspondyloarthritispatientsreceivingbiologicaltherapy AT kddorogoikina qualityoflifeinspondyloarthritispatientsreceivingbiologicaltherapy AT izgaydukova qualityoflifeinspondyloarthritispatientsreceivingbiologicaltherapy AT aprebrov qualityoflifeinspondyloarthritispatientsreceivingbiologicaltherapy |